LOOKING FORWARD TO THE FUTURE
As the toughest cancers adapt and evolve, our approach in turn must be
innovative and agile in the � ght against cancer. Amgen continues to take on
some of the toughest cancers, and this effort requires a greater understanding
of the pathophysiology of cancer cells and the identi� cation of new targets
and signaling pathways so that novel oncologic therapies may be developed.
The last two decades have seen remarkable progress, with scientific
breakthroughs in genetics, molecular biology, and biotechnology. These
advances have led to the emergence of biologic therapies and immunotherapies,
which have now become important components of cancer therapy.10 More
recently, a greater appreciation of the human immune system has inspired
the development of therapies that use the body's immune response. In fact,
immuno-oncology may herald the beginning of an era that holds great promise
for the long-term control of many cancer types.
References: 1. Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer
Discov. 2012;2:214-226. 2. Ellis LM, Hicklin DJ. Resistance to targeted therapies: re� ning anticancer therapy in the era
of molecular oncology. Clin Cancer Res. 2009;15:7471-7478. 3. Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B,
Cruceru ML. Anti-cancer therapies in high grade gliomas. Curr Proteomics. 2013;10:246-260. 4. Henley SJ, King JB,
German RR, Richardson LC, Plescia M. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix)
- United States, 2004-2006. MMWR Surveillance Summaries. 2010;59:1-25. 5. Cancer multidrug resistance. Nature
America Inc. 2000;IT18-IT20. 6. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical
perspective. Cancer Res. 2010;70:5649-5669. 7. Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers
are transforming our understanding and management of advanced gastric cancer. The Oncologist. 2014;19:1-10.
8. National Cancer Institute at National Institutes of Health. Genomic understanding of glioblastoma expanded.
www.cancer.gov/newscenter/newsfromnci/2013/gbm500. Accessed September 17, 2014. 9. Batchelor T, Louis DN.
Pathology and molecular pathogenesis of diffuse gliomas. UpToDate. 2014:1-18. 10. American Cancer Society. History of
cancer. www.cancer.org. Accessed September 18, 2014.
© 2015 Amgen Inc. All rights reserved. Not for Reproduction. 83321-R1-V1
Our researchers are investigating a number of
targeted agents to take on the toughest cancers.
Look for more in this series at amgenoncology.com
as we continue to take on the toughest cancers.
TAKING ON THE TOUGHEST CANCERS.